Drug intelligence / Profile preview

I-125-OI5V

Development stage
Preclinical
Lead developer
Kanazawa University
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
Administration
Intravenous
01

Overview

I-125-OI5V (also known as 125I-OI5V or 125I-2-[4-(2-iodophenyl)piperidino]cyclopentanol) is a radiolabeled vesamicol analog with a five-membered ring structure that acts as a highly selective imaging probe for the sigma-1 receptor (σ1R). Developed by researchers at Kanazawa University, this single-photon emission computed tomography (SPECT) tracer is designed to non-invasively map and monitor the spatiotemporal expression of σ1R, which is upregulated in response to cellular stress such as myocardial ischemia and reperfusion injury, as well as doxorubicin-induced cardiotoxicity. By binding selectively to σ1R, I-125-OI5V serves as a valuable diagnostic tool in preclinical research to evaluate the severity of ischemic burden and assess myocardial viability.

Other names
125I-2-[4-(2-iodophenyl)piperidino]cyclopentanol125I-OI5V125I-labeled 2-[4-(2-iodophenyl)piperidino]cyclopentanolI-125-labeled OI5VI125-labeled OI5VI 125-labeled OI5VI-125iodophenyl-piperidino-cyclopentanolI125iodophenyl-piperidino-cyclopentanolI 125iodophenyl-piperidino-cyclopentanolI-125iodophenyl-piperidino-cyclopentanoneI125iodophenyl-piperidino-cyclopentanoneI 125iodophenyl-piperidino-cyclopentanone
02

Targets

SIGMAR1 (Sigma non-opioid intracellular receptor 1)

Beyond the preview

Go deeper on I-125-OI5V.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on I-125-OI5V.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call